GLP-1 Discontinuation Rates Prompt Microdosing Trend

Over one million people discontinue GLP-1 therapy each month, reflecting significant challenges in patient adherence, according to Dr. Chris Thompson.

Approximately 30% of patients stop GLP-1s in the first month, with this figure rising to about 50% by the end of the first year, a pattern Dr. Thompson notes is not unique to GLP-1s but common across chronic medications like those for blood pressure and cholesterol.

Patients discontinue GLP-1s due to various factors, including the difficulty of remembering daily oral medications and the phenomenon of needle fatigue associated with weekly injections.

Significant side effects such as nausea and muscle loss are frequently cited, alongside psychological hesitancy stemming from the unknown long-term ramifications of taking super-physiological doses, as explained by Dr. Chris Thompson.

Standard dosage protocols often reflect the constraints of clinical trial costs more than individual physiological needs, a gap that leads many to pursue personalized microdosing strategies, according to Dr. Chris Thompson.

Standard dosage protocols are often influenced by the high costs of clinical trials, which may not align with individual physiological needs, thereby limiting personalized treatment approaches.

Microdosing offers a pathway towards precision medicine by allowing individuals to tailor their dosage, as exemplified by a physician patient who successfully managed weight and reduced side effects using a sterile vial and insulin syringe method.

GLP-1s are typically intended as lifelong medications, and stopping them suddenly can lead to complications, making microdosing a strategic approach to sustain benefits without high-dose side effects.

Approximately one-third of the weight lost while on GLP-1 medications consists of lean mass, including muscle and potentially bone.

Cycling on and off these drugs leads to a problematic yo-yo effect where weight is regained primarily as fat, not lean mass, progressively worsening body composition with each cycle, according to Chris Thompson.

Consequently, a formal strategy, such as continuous microdosing or bridging to other weight management procedures, is essential for individuals considering discontinuation to mitigate these adverse shifts.

When the body experiences a caloric deficit, it naturally seeks ways to maintain energy levels; engaging in resistance training signals the body to preserve muscle tissue rather than breaking it down for energy.

Concerns regarding apathy and a diminished 'appetite for life' are often amplified on social media, out of proportion to actual clinical data, according to Dr. Andrew Huberman and Dr. Chris Thompson.

While reports of GLP-1 induced blindness are linked to very rare cases of optic nerve head ischemia, muscle loss, encompassing phenomena like 'Ozempic face' or 'Ozempic butt' and sarcopenia, remains the most consistent and significant clinical concern, particularly for patients with low initial muscle mass who do not exercise.

Social media often amplifies reports of apathy and decreased 'appetite for life,' creating narratives that may not align with comprehensive clinical data, Dr. Andrew Huberman observed.

Dr. Chris Thompson notes that while these reports are prevalent online, their accuracy and widespread applicability require careful scrutiny, highlighting a distinction between online discourse and clinical reality.

Blindness associated with GLP-1s has been reported in a very small subset of individuals with specific optic nerve head ischemia, not as a generalized risk for all patients, Dr. Chris Thompson clarified.

Dr. Thompson recommends that individuals undergo screening for underlying structural eye issues before initiating GLP-1 medication to identify and mitigate this rare risk.

DEXA scans are recommended by Dr. Chris Thompson to differentiate between aesthetic concerns like 'Ozempic face' and the clinical risk of sarcopenia, which occurs most frequently in patients with low baseline muscle mass.

Sarcopenia is more prevalent in patients who begin with low muscle mass and do not engage in regular exercise.

Dr. Thompson advises patients to undergo a DEXA scan before starting GLP-1s to assess baseline muscle mass and recommends that those with inadequate muscle mass either reconsider the medication or prioritize strength training.

Nausea is a primary factor driving patients to discontinue or struggle with tolerating GLP-1 medications, particularly at higher doses, according to Dr. Chris Thompson.

Many patients find themselves in a dilemma where lower doses fail to induce weight loss, but higher, effective doses cause intolerable gastrointestinal side effects, leading to a 'stalling' of weight loss progress.